The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Zanubrutinib, which is a type of treatment known as a BTK inhibitor, specifically for patients with Chronic Lymphocytic Leukemia (CLL) in China. The goal of the study is to gather real-world information about how effective this treatment is for people diagnosed with CLL who need therapy. While the trial is not yet recruiting participants, it aims to include adults aged 18 and older who have been diagnosed with CLL and either have not received treatment before or have CLL that has come back after previous treatments.

To be eligible for this study, participants must have started treatment with a BTK inhibitor and have been using it for at least three months. They will also need to have had at least one follow-up appointment during their treatment. If you or someone you know is considering participation, it’s important to understand that the study will collect information on how well the treatment works in everyday practice, which can help improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged ≥18 years old
• • 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)；
• • 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
• • 4. Prior or current use of BTK inhibitor for ≥3 months
• • 5. At least one follow-up was recorded during BTK inhibitor treatment